Article
The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2013
Choueiri Toni K, Fay André P, Gagnon Robert, Lin Ying, Bahamon Brittany, Brown Victoria, Rosenberg Jonathan E, Hutson Thomas E, Baker-Neblett Katherine L, Carpenter Christopher, Liu Yuan, Pandite Lini, Signoretti Sabina
Abstract excerpt
PURPOSE: Inactivation of von Hippel-Lindau (VHL) gene in clear-cell renal cell carcinoma (RCC) leads to increased levels of hypoxia-inducible factors (HIF) and overexpression of HIF target genes, such as VEGF and others. VEGF-targeted agents are standard in advanced clear-cell RCC but biomarkers of activity are lacking. EXPERIMENTAL DESIGN: We analyzed tumor tissue samples from metastatic clear-cell RCC patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
